谈判马拉松后拿出来的诚意 在GSK道歉之外

“GSK plc sincerely apologises to the Chinese patients, doctors and hospitals, and to the Chinese government and the Chinese people . . .”

“葛兰素史克总公司(GSK plc)向中国患者、医生、医院和中国政府、全体中国人民深刻道歉……”

It is quite something for a company to apologise to 1.3bn people all at once. Focus on the doctors. They are the reason for the Rmb3bn fine (nearly $500m) which GlaxoSmithKline must pay in China.

对一家公司而言，向13亿人一并道歉，不是件易事。把焦点放在医生身上吧。他们才是GSK必须向中国支付30亿元人民币(合近5亿美元)罚金的原因。

GSK’s Chinese subsidiary was found guilty of bribery on Friday after a year-long investigation. The stock market was never bothered. The shares moved little when the investigation, and then the fine, were disclosed. China may be too small to matter much for now. It is under 3 per cent of GSK’s sales. And one might assume that China will continue to grow without much cost. After all, GSK’s apology does not suggest its Chinese business will face formal oversight – unlike banks who pay fines to US regulators and must host embedded “compliance offices”.

上周五，在经过长达一年的调查后，GSK中国分公司被认定犯有行贿罪。GSK股票从未收到此次调查的影响。当调查结果公布时、以及罚金被披露时，股价都几无变动。中国市场给GSK贡献的收入可能还太小，占GSK销售额的不到3%。人们可能会认为，中国市场将会继续增长，而成本不会大幅上升。毕竟，GSK的道歉并不表明其中国业务被监管机构正式“盯上”了——不像那些向美国监管机构支付罚金的银行，它们必须建立“合规办公室”。

A fine, an apology and a rethink of practices might seem to be enough. Except for the doctors. They are not paid much. One of the country’s top physicians told the National People’s Congress this year that the annual incomes of hospital doctors in Guangzhou are four times their official salaries. China’s drugs market is $80bn in size – third largest in the world, with four-fifths of sales via hospitals. If the physician is right about the gap between salary and income, there will be more drug company investigations.

处罚、道歉、重审业务模式——GSK做的看上去已经够多了。但别忘了中国医生。中国医生的工资不高。一位顶尖的医生今年曾在全国人大(NPC)表示，在广州，医生的实际年收入是他们正常工资的4倍。中国药品市场规模为800亿美元，居全球第三，其中五分之四的销售额是通过医院实现。如果这位医生有关工资和实际收入差距的言论是正确的，那么未来将出现更多的针对制药公司的调查。

GSK’s apology is for improperly paying “non-government personnel”: a euphemism for doctors. And beyond the changes it promises for the Chinese business – price cuts – GSK will stop payments to doctors for junkets and revise how it pays salespeople. That is likely to mean revenues – one of the few parts of its China business that GSK discloses – will slow. In any case, shareholders in GSK and other pharma groups should demand to know much more about their companies’ Chinese businesses. This story is not over.

GSK此次道歉，是因为它不正当地给予“非国家工作人员”（这是对医生的委婉说法）财物。除了承诺在中国改革（也就是降价）之外，GSK将停止向医生支付旅游费用，并修改其销售人员的工资计算方式。这可能意味着，收入将减少（收入是GSK公布的有关其中国业务为数不多的信息之一）。不论怎样，GSK和其他制药企业的股东都应当要求这些公司披露更多在华业务信息。故事还没有结束。